Condition
Pulmonary Hypertension Due to Lung Diseases
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT04691154Phase 3Active Not Recruiting
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
NCT07498244RecruitingPrimary
Collagen Fingerprinting for Stratification of PH Patients
NCT07478094Not Yet RecruitingPrimary
Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost
NCT06336798Phase 2Recruiting
Bioenergetic Effect of Pioglitazone in CLD-PH
Showing all 4 trials